All News
Race to the top: how high will treatment response rates in RA reach?
We have become accustomed to the 60/40/20% rule for the outcome of ACR 20/50/70 respectively for biologics and targeted synthetic DMARDs.
Read Article
Plotting Future ACR Convergence Meetings (11.24.2023)
In this week's podcast, Dr. Jack Cush reviews the ACR Convergence 2023 meeting and proposes how to best learn at your next large medical meeting.
Read Article
Reconsidering Steroids
There is not a single one of us in rheumatology who hasn’t prescribed steroids, but we really need to reconsider how much and how often we use them.
Read Article
Reduction of AxSpa-Associated Acute Anterior Uveitis with Certolizumab
Acute anterior uveitis (AAU) is the most common extra-musculoskeletal manifestation in axial spondyloarthritis (axSpA), affecting up to 50% of patients in some age groups.
https://t.co/uhlnpmLwoP https://t.co/NRW0PlD43a
Dr. John Cush RheumNow ( View Tweet)
Undiagnosed IBD in AxSpA
Dr. Eric Dein (Summit, New Jersey) discusses Abstract #0495 presented at the ACR 2023 Convergence meeting in San Diego.
https://t.co/QAC6fhSQ7Q https://t.co/BxNQwQ9nwc
Dr. John Cush RheumNow ( View Tweet)
The impact of SGLT2-inhibitor on SLE outcomes
SLE is associated with increased risk of cardiovascular events due to both traditional and disease-specific risk factors.
https://t.co/hyyMVQg3xV https://t.co/fLxh0vlTze
Dr. John Cush RheumNow ( View Tweet)
Are Rheumatologists doing Enough for Cervical Cancer?
Should rheums be counseling patients on cervical cancer prevention and screening? The data from Abstract #1479 at #ACR23 suggests this should be an important conversation with our lupus patients.
https://t.co/VFobM0T3u7 https://t.co/L45N3tsTdN
Dr. John Cush RheumNow ( View Tweet)
Substudy of the ADVOCATE trial looked at 214 ANCA assoc vasculitis pts treated with #RTX; avacopan Rx showed improved recovery of renal function, faster reduction in albuminuria and lower glucocorticoid toxicity compared to a prednisone taper. https://t.co/91PtvQfoIr https://t.co/ZjYCVP5lqG
Dr. John Cush RheumNow ( View Tweet)
Long term F/U of early RA, T2T RCTs (n 1616) finds excess mortality > 10yrs for BeST (SMR 1.32) & IMPROVED (SMR 1.33) RCTs; highest in ACPA+ smokers (SMR 2.80 & 2.14); Cancer main cause. SMR incr 34% & 13% for ea 1 pt incr in DAS https://t.co/2DdHMGIlOk https://t.co/7bnCOzB8vd
Dr. John Cush RheumNow ( View Tweet)
Infections During Treatment of GPA with Rituximab
Dr. Richard Conway (Dublin, Ireland) discusses abstract 1584 presented at the 2023 ACR Convergence meeting in San Diego, CA.
https://t.co/eKi3KExEnk https://t.co/b9G9w5e9tc
Dr. John Cush RheumNow ( View Tweet)
Watch and Weigh In: Upadacitinib for Pain: Is That Real?
Dr. David Liew reports on abstract 0429 at the 2023 ACR Convergence meeting in San Diego, CA.
https://t.co/AbD9UpXQfY https://t.co/iRgUnNInuD
Dr. John Cush RheumNow ( View Tweet)
Computer Vision: Is It Ready for RA Assessment?
Dr. David Liew reports on abstract 0402 and 1293 at the 2023 ACR Convergence meeting in San Diego, CA.
https://t.co/4rQDjFXjH2 https://t.co/8FM40kh3bw
Dr. John Cush RheumNow ( View Tweet)
Hemophagocytic Lymphohistiocytosis in Still's Disease
Dr. Bella Mehta discusses abstract 1143 presented at the 2023 ACR Convergence meeting in San Diego, CA.
https://t.co/bFeGK6MTcc https://t.co/cxJg6rQ7gm
Dr. John Cush RheumNow ( View Tweet)
Watch: Deep Neural Networks and Radiographic Progression in AxSpA
Dr. Antoni Chan discusses abstracts 1389 and 1398 presented at the 2023 ACR Convergence in San Diego, CA.
https://t.co/F9hpNvmvVc https://t.co/xR0uW1CkUw
Dr. John Cush RheumNow ( View Tweet)
The impact of SGLT2-inhibitor on SLE outcomes
SLE is associated with increased risk of cardiovascular events due to both traditional and disease-specific risk factors.
https://t.co/BjjerQhsrR https://t.co/vpzSaAIOjU
Dr. John Cush RheumNow ( View Tweet)
Are Rheumatologists doing Enough for Cervical Cancer?
Should rheums be counseling patients on cervical cancer prevention and screening? The data from Abstract #1479 at #ACR23 suggests this should be an important conversation with our lupus patients.
https://t.co/FKaLSiBHV6 https://t.co/zR46JU5mlR
Dr. John Cush RheumNow ( View Tweet)
Combined 4 tofacitinib RCTs (4404 pts) found baseline probable major depression or anxiety disorder in 44.5%, 39.8%, 45.4%, 39.1% on TOFA 5 BID, TOFA 10 BID, adalimumab, & placebo. Effective RA Rx w/ Tofa or ADA lead to improved depression and anxiety https://t.co/y6UoFXANo7 https://t.co/aV5uV9qWbz
Dr. John Cush RheumNow ( View Tweet)
#PsA Metanalysis of 54 RCTs (22621 pts; 49% male). Males had less severe Dz than females (TJC, HAQ, global, pain) but higher PASI & CRP. Males had higher ACR20 resp to inhib of IL-17 (OR 1.7), IL-23 (1·46), 12/23 (2·67), TNF (1·55) but no diff w/ JAK/Tyk2 https://t.co/fOl9zpCv1G https://t.co/JXAj5sG1bf
Dr. John Cush RheumNow ( View Tweet)
Substudy of the ADVOCATE trial looked at 214 ANCA assoc vasculitis pts treated with #RTX; avacopan Rx showed improved recovery of renal function, faster reduction in albuminuria and lower glucocorticoid toxicity compared to a prednisone taper. https://t.co/ujynO9oAj0 https://t.co/JWBrKzGux1
Dr. John Cush RheumNow ( View Tweet)
MSK disorders affects >1.63 billion worldwide. Global Burden of Diseases study estimates that by 2050, 1.06 billion will have "other" MSK Dz (excluding RA, OA, LBP, gout, neck pain) - up from 494 million in 2020. https://t.co/cCf8biqjx1 https://t.co/Xv9qlvQl90
Dr. John Cush RheumNow ( View Tweet)